The estimated Net Worth of Joe Newell is at least $2.26 million dollars as of 16 November 2021. Joe Newell owns over 3,332 units of Atara Biotherapeutics Inc stock worth over $939,836 and over the last 7 years Joe sold ATRA stock worth over $1,317,176.
Joe has made over 34 trades of the Atara Biotherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Joe sold 3,332 units of ATRA stock worth $57,044 on 16 November 2021.
The largest trade Joe's ever made was exercising 10,500 units of Atara Biotherapeutics Inc stock on 22 September 2021 worth over $127,575. On average, Joe trades about 2,783 units every 29 days since 2017. As of 16 November 2021 Joe still owns at least 113,097 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Joe Newell stock trades at the bottom of the page.
Joe's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier et Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: